Novo's liraglutide gets CHMP green light for obesity
This article was originally published in Scrip
Novo Nordisk's GLP-1 agonist product Saxenda (liraglutide) has won a recommendation for regulatory approval from the European Medicine Agency's CHMP for use in obesity. The drug, which is already marketed as Victoza at lower doses for diabetes, is not hampered by safety concerns that have hindered other anorectics, and is thought likely to perform well.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.